Hematopoietic stem/progenitor cells
Hematopoietic Stem Cells (HSC) are cells isolated primarily from bone marrow and umbilical cord blood. They can self-renew and differentiate into many different types of blood cells.
These characteristics raised the interest of researchers in using them as potential cellular treatment for a variety of diseases over 50 years ago. Nowadays, transplant of HSC is routinely used as therapy for several cancers, blood or immune disorders and metabolic diseases. Moreover, research progress could widen the therapeutic window of HSC transplants to treat brain disorders such as Alzheimer or Dementia, or neurodegenerative diseases such as Multiple Sclerosis, amongst others.
In vitro challenges
In vitro cultures of HSC still represent a challenge in research because their fragility prevents them from replicating and also because, in order to differentiate, samples of HSC must be cultured with a highly specific combination of cytokines. Additionally, given their similarity to many other blood or bone marrow cells, purifying HSC is a challenge, and the fact that only 1:10000-15000 bone marrow cells or 1:100000 blood cells is known to be a stem cell does not ease the task.
To address the identification problem, cell surface protein markers can be used. One of the most commonly used markers for HSC recognition is CD34, a transmembrane phosphoglycoprotein encoded by the gene with the same name. CD34+ HSC isolated from umbilical cord blood present the advantage to efficiently proliferate without losing their ability to differentiate into the several blood cell types.